The Advantage of Bevacizumab in Treating Colorectal Brain Metastasis

Abstract Bevacizumab is known to be a humanized monoclonal antibody that inhibits vascular endothelial growth factor. It is used to treat varied kinds of cancers, such as breast cancer, colorectal cancer, non-small cell lung cancer, high grade glioma and etc. While it do appear to delay cancer progr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Cancer Research and Practice 2014-09, Vol.1 (2), p.146-151
Main Authors: 陳鴻明(Hung-Ming Chen), 鄧豪偉(Hao-Wei Teng)
Format: Article
Language:English
Subjects:
avastin
bevacizumab
biochemotherapy
brain metastasis
colorectal cancer
Hematology, Oncology and Palliative Medicine
TSCI
生物化學治療
癌思停
結腸直腸癌
腦轉移
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Bevacizumab is known to be a humanized monoclonal antibody that inhibits vascular endothelial growth factor. It is used to treat varied kinds of cancers, such as breast cancer, colorectal cancer, non-small cell lung cancer, high grade glioma and etc. While it do appear to delay cancer progression, it is not a curative approach. Because of its high molecular weight, bevacizumab would be believed to be not cross the blood- brain barrier. However, this theory is to be challenged by series of studies proving the efficacy of bevacizumab in brain tumor. On account of lack of vital information about safety events and increasing risk of intra-cranial hemorrhage, Food and Drug Administration (FDA) lifted the ban on use of bevacizumab in colorectal cancer with brain metastasis since several years ago. Therefore, the reports of use of bevacizumab in colorectal cancer with brain metastasis are limited. Here, we presented a case of colorectal cancer with brain metastasis, and the brain lesion got shrinkage after starting bevacizumab in combination with chemotherapy.
ISSN:2311-3006
2311-3006
DOI:10.6323/JCRP.2014.1.2.08